Genzyme, Isis in $325 million cardio drug pact
January 10 2008
Genzyme has entered into a $325 million licensing deal with Isis Pharmaceuticals to commercialize mipomersen, Isis' lipid-lowering treatment for high-risk ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.